SP4206
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
SP4206 is an experimental drug which is described as a small molecule protein-protein interaction inhibitor. It binds with high affinity to interleukin-2 at the precise residues which usually mediate binding between interleukin-2 and the IL-2 receptor, thereby preventing binding and blocking the action of interleukin-2 in the body. Interleukin-2 is a cytokine signalling molecule with an important role in the function of the immune system, and most medical interest has been in enhancing interleukin-2 activity for the treatment of cancer. However, it is also involved in some autoimmune disease processes, and blocking interleukin-2 activity with SP4206 has been researched for the treatment of atopic asthma, which is commonly associated with elevated interleukin-2 levels.
SP4206 is an experimental drug which is described as a small molecule protein-protein interaction inhibitor. It binds with high affinity to interleukin-2 at the precise residues which usually mediate binding between interleukin-2 and the IL-2 receptor, thereby preventing binding and blocking the action of interleukin-2 in the body. Interleukin-2 is a cytokine signalling molecule with an important role in the function of the immune system, and most medical interest has been in enhancing interleukin-2 activity for the treatment of cancer. However, it is also involved in some autoimmune disease processes, and blocking interleukin-2 activity with SP4206 has been researched for the treatment of atopic asthma, which is commonly associated with elevated interleukin-2 levels.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1330496890 under CC BY-SA 4.0; modifications have been made.